StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Intercept Pharmaceuticals (ICPT) PT Raised to $175 at Oppenheimer; 'REGENERATE Top Line Sparks Joy'
February 19, 2019 1:03 PM
Oppenheimer analyst Jay Olson raised the price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $175.00 (from $140.00) while maintaining a ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Next Articles
Intercept Pharma (ICPT) Gives Back Most of NASH Trial Gains
February 20, 2019 11:29 AM
Intercept Pharmaceuticals (ICPT) PT Raised to $149 at Cowen
February 19, 2019 4:12 PM
Intercept Pharmaceuticals (ICPT) PT Raised to $248 at Wedbush
February 19, 2019 1:57 PM
Buy Galmed Pharma (GLMD) On Galmed/OCA Combo - Cantor
February 19, 2019 12:13 PM
Two Key Intercept Pharma (ICPT) Takeaways From REGENERATE Results - Roth
February 19, 2019 10:42 AM
Intercept Pharmaceuticals (ICPT) Bullish View Reiterated at Needham & Company on Positive Positive Phase 3 REGENERATE NASH Trial
February 19, 2019 10:42 AM
Intercept Pharma (ICPT) Estimates Raised At Baird
February 19, 2019 9:51 AM
Viking Therapeutics (VKTX) Trades Higher Following Positive Results From Intercept Pharma (ICPT)
February 19, 2019 7:41 AM
Intercept Pharma (ICPT) Announces Phase 3 REGENERATE Study in NASH Met Primary Endpoint
February 19, 2019 7:03 AM
